Review Article
Mesoglycan: Clinical Evidences for Use in Vascular Diseases
Table 2
Mesoglycan in peripheral obstructive arterial disease (POAD). Clinical studies.
| Author | Study design | Pathology | Patients () | Doses/route | Results |
| Andreozzi [18] | Prospective | POAD in stages I-II Fontaine | 10 | Mesoglycan 60 mg daily for 20 days | Mesoglycan: safe and effective in improving the wall response to vasodilator stimulus | Raso [19] | Prospective | POAD stage IIb Fontaine | 36 | Mesoglycan 60 mg daily endovenous for 10 days then 100 mg daily orally for 20 days, repeated for two months then oral mesoglycan for 12 months | Mesoglycan: significant improvement of symptoms and signs in all patients but one | Nenci [20] | Randomized, double-blinded | PAOD stage II Fontaine | 242 | Mesoglycan 30 mg daily i.m. for 3 weeks then 100 mg daily orally for two weeks, versus matching placebo All patients receive ASA | Mesoglycan: significant clinical improvement versus placebo. Significant improvement in quality of life scores. |
|
|